Form 4: Director John Tincoff III Acquires Vyome Holdings Stock Options

Vyome Holdings Director John Tincoff III was granted 17,833 stock options following the merger with Vyome Therapeutics, Inc.

Summary

• John M. Tincoff III, a Director of Vyome Holdings, Inc. (HIND), reported changes in beneficial ownership on November 13, 2025.
• He acquired 17,833 stock options to purchase shares of Vyome Holdings common stock at an exercise price of $0.66 per share.
• These options were granted under the Issuer's 2025 Equity Incentive Plan.
• The grant is a direct result of the Agreement and Plan of Merger, dated July 8, 2024, where Vyome Therapeutics, Inc. merged into a subsidiary of the Issuer.
• Following the merger, the Issuer was renamed "Vyome Holdings, Inc.", and options to purchase Vyome Therapeutics common stock were converted into options for Vyome Holdings common stock.
• Of the 17,833 options, 4,458 were fully vested as of the grant date.
• The remaining 13,375 options will vest in twelve equal monthly installments beginning on November 30, 2025, contingent on Mr. Tincoff's continued service.
• The stock options have an expiration date of July 30, 2035.

Sentiment

Score: 6

Explanation: The filing reports a director's acquisition of stock options as part of a post-merger compensation package. This is a neutral to slightly positive event as it aligns insider interests with the company's future performance, but it's not an open market purchase indicating strong conviction.

Positives

• Director John M. Tincoff III acquired 17,833 stock options, aligning his long-term interests with those of Vyome Holdings shareholders.
• A portion of the options (4,458) vested immediately upon grant, providing immediate equity exposure.

Risks

• The vesting of 13,375 stock options is contingent upon the Reporting Person's continued service, meaning full realization of these options is at risk if service ceases before all installments vest.

Future Outlook

The future outlook for the reporting person's equity ownership includes the vesting of 13,375 stock options in twelve equal monthly installments beginning November 30, 2025, contingent on continued service.

Industry Context

This filing reflects a standard post-merger compensation event for a director, aligning their incentives with the newly formed entity, Vyome Holdings, Inc. Such grants are common in the biotechnology or pharmaceutical sectors following significant corporate restructuring like mergers, aiming to retain key personnel and integrate leadership.

Comparison to Industry Standards

• The grant of stock options to a director following a merger is a common practice in the industry to incentivize long-term commitment and align interests with shareholders, similar to compensation structures seen in companies like Pfizer or Johnson & Johnson post-acquisition.
• The vesting schedule, with a portion immediately vested and the remainder vesting over a period, is a standard approach to balance immediate reward with retention incentives, comparable to equity compensation plans at biotech firms such as Moderna or Gilead Sciences.

Corporate Governance

Stakeholder Impact

• Shareholders: The grant of stock options to a director aligns management's long-term interests with shareholder value creation.
• Employees (specifically the reporting person): The options provide a significant equity incentive and compensation component, subject to continued service.

Next Steps

• The remaining 13,375 stock options will vest in twelve equal monthly installments beginning November 30, 2025.
• Continued service of the Reporting Person is required for the vesting of the remaining options.

Key Dates

Keywords

Vyome Holdings, HIND, Stock Options, Insider Transaction, Form 4, Merger Agreement, Equity Incentive Plan, Director Compensation